Jim Herrmann

Jim is a financial and operations executive with over 25 years experience spanning finance, product development, manufacturing and regulatory, in both diagnostics and therapeutics. Jim co-founded Tolera Therapeutics, where he worked with CEO John Puisis to raise $20 million and bring its MAb therapy from pre-clinical to a Phase 3 Special Protocol Assessment. Prior to this, Jim served as CFO for Third Wave Technologies (NASDAQ: TWTI), where he oversaw long-range and annual planning, company-wide systems and infrastructure development, operational management as well as quality system oversight. Jim oversaw the company’s first FDA 510k filing for a molecular diagnostic and the launch of its multiplexing diagnostic platform. Jim is a graduate of the University of Notre Dame and the University of Chicago (MBA).

Jim Herrmann is the CFO / COO at Cour Pharmaceuticals Development, based in United States, North America. With a background in Biotechnology, Jim Herrmann has a rich history of leadership and innovation.Jim Herrmann studied MBA unknown at University of Chicago. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.